Graft-versus-host disease historical perspective: Difference between revisions
Jump to navigation
Jump to search
Shyam Patel (talk | contribs) |
Shyam Patel (talk | contribs) |
||
| Line 14: | Line 14: | ||
*In 1959, the work done by Billingham and Brent work was published. | *In 1959, the work done by Billingham and Brent work was published. | ||
*In 1962, Barnes and colleagues noted that mice who were lethally irradiated then treated with a bone marrow xenograft developed a secondary disease.<ref name="pmid27011200">{{cite journal| author=Villa NY, Rahman MM, McFadden G, Cogle CR| title=Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies. | journal=Viruses | year= 2016 | volume= 8 | issue= 3 | pages= 85 | pmid=27011200 | doi=10.3390/v8030085 | pmc=4810275 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27011200 }} </ref> This article was called "Secondary disease of radiation chimeras: a syndrome due to lymphoid aplasia." This seminal paper helped to define what we know today about the pathophysiology of GvHD.<ref name="pmid27011200">{{cite journal| author=Villa NY, Rahman MM, McFadden G, Cogle CR| title=Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies. | journal=Viruses | year= 2016 | volume= 8 | issue= 3 | pages= 85 | pmid=27011200 | doi=10.3390/v8030085 | pmc=4810275 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27011200 }} </ref> | |||
*In 1966, Billingham described 3 prerequisites for GvHD.<ref name="pmid27011200">{{cite journal| author=Villa NY, Rahman MM, McFadden G, Cogle CR| title=Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies. | journal=Viruses | year= 2016 | volume= 8 | issue= 3 | pages= 85 | pmid=27011200 | doi=10.3390/v8030085 | pmc=4810275 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27011200 }} </ref> The first prerequisite is the existence of immunocompetent cells in the donor tissue. The second prerequisite is the presence of allelic disparities, or histocompatibility differences, between the donor and the recipient. The third prerequisite is the impaired ability of the recipient to reject the donor cells.<ref name="pmid27011200">{{cite journal| author=Villa NY, Rahman MM, McFadden G, Cogle CR| title=Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies. | journal=Viruses | year= 2016 | volume= 8 | issue= 3 | pages= 85 | pmid=27011200 | doi=10.3390/v8030085 | pmc=4810275 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27011200 }} </ref> | |||
In 1978, Korngold and Sprent noted that the cellular mediators of GvHD are mature donor T cells.<ref name="pmid27011200">{{cite journal| author=Villa NY, Rahman MM, McFadden G, Cogle CR| title=Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies. | journal=Viruses | year= 2016 | volume= 8 | issue= 3 | pages= 85 | pmid=27011200 | doi=10.3390/v8030085 | pmc=4810275 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27011200 }} </ref> | |||
*In 1990, Weisdorf and colleagues from the University of Minnesota made a seminal discovery after analyzing the long-term outcomes for patients with gradfes II-IV GvHD after stem cell transplant.<ref name="pmid2302454">{{cite journal| author=Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N et al.| title=Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. | journal=Blood | year= 1990 | volume= 75 | issue= 4 | pages= 1024-30 | pmid=2302454 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2302454 }} </ref> After treatment with steroids, it was noted that 41% of patients achieved a complete remission after 3 weeks of therapy.<ref name="pmid2302454">{{cite journal| author=Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N et al.| title=Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. | journal=Blood | year= 1990 | volume= 75 | issue= 4 | pages= 1024-30 | pmid=2302454 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2302454 }} </ref> There was a 5-year survival advantage (51% vs. 32%) in patients who had achieved complete remission from GvHD.<ref name="pmid2302454">{{cite journal| author=Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N et al.| title=Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. | journal=Blood | year= 1990 | volume= 75 | issue= 4 | pages= 1024-30 | pmid=2302454 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2302454 }} </ref> | *In 1990, Weisdorf and colleagues from the University of Minnesota made a seminal discovery after analyzing the long-term outcomes for patients with gradfes II-IV GvHD after stem cell transplant.<ref name="pmid2302454">{{cite journal| author=Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N et al.| title=Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. | journal=Blood | year= 1990 | volume= 75 | issue= 4 | pages= 1024-30 | pmid=2302454 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2302454 }} </ref> After treatment with steroids, it was noted that 41% of patients achieved a complete remission after 3 weeks of therapy.<ref name="pmid2302454">{{cite journal| author=Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N et al.| title=Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. | journal=Blood | year= 1990 | volume= 75 | issue= 4 | pages= 1024-30 | pmid=2302454 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2302454 }} </ref> There was a 5-year survival advantage (51% vs. 32%) in patients who had achieved complete remission from GvHD.<ref name="pmid2302454">{{cite journal| author=Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N et al.| title=Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. | journal=Blood | year= 1990 | volume= 75 | issue= 4 | pages= 1024-30 | pmid=2302454 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2302454 }} </ref> | ||
Revision as of 16:58, 19 June 2017
|
Graft-versus-host disease |
|
Differentiating Graft-versus-host disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Graft-versus-host disease historical perspective On the Web |
|
American Roentgen Ray Society Images of Graft-versus-host disease historical perspective |
|
Graft-versus-host disease historical perspective in the news |
|
Risk calculators and risk factors for Graft-versus-host disease historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Shyam Patel [2]
Overview
The history of GvHD dates back to the 1910s, when an immunologic reaction was observed in chick embryos. Since that time, many advances have been made with regards to our understanding of the disease.
Historical Perspective
GvHD was recognized many years ago in the 1950s.
- In 1916, GvHD was first observed at the Rockefeller Institute in New York City. An immunologic reaction was noticed after engrafting adult chicken tissue containing T cells onto the chorioamnionic membrane of chick embryos.[1] At that time, the concept of T cells was in its infancy. Prior to that time, there was no suggestion of a link between GvHD and T cells.[1]
- In 1957, Billingham and Brent noticed unexpected findings. They noticed that mice who were chimeric were becoming very sick and were termed "runts." It was eventually discovered that immunocompetent cells from neonatal inocula could migrate to areas of host lymphoid tissue and mount an attack.[1] In the same year, Morton Simonsen showed evidence of GvHD in chickens. He had injected allogeneic lymphoid cells into chick embryos.[1]
- In 1959, the work done by Billingham and Brent work was published.
- In 1962, Barnes and colleagues noted that mice who were lethally irradiated then treated with a bone marrow xenograft developed a secondary disease.[2] This article was called "Secondary disease of radiation chimeras: a syndrome due to lymphoid aplasia." This seminal paper helped to define what we know today about the pathophysiology of GvHD.[2]
- In 1966, Billingham described 3 prerequisites for GvHD.[2] The first prerequisite is the existence of immunocompetent cells in the donor tissue. The second prerequisite is the presence of allelic disparities, or histocompatibility differences, between the donor and the recipient. The third prerequisite is the impaired ability of the recipient to reject the donor cells.[2]
In 1978, Korngold and Sprent noted that the cellular mediators of GvHD are mature donor T cells.[2]
- In 1990, Weisdorf and colleagues from the University of Minnesota made a seminal discovery after analyzing the long-term outcomes for patients with gradfes II-IV GvHD after stem cell transplant.[3] After treatment with steroids, it was noted that 41% of patients achieved a complete remission after 3 weeks of therapy.[3] There was a 5-year survival advantage (51% vs. 32%) in patients who had achieved complete remission from GvHD.[3]
References
- ↑ 1.0 1.1 1.2 1.3 Barker CF, Markmann JF (2013). "Historical overview of transplantation". Cold Spring Harb Perspect Med. 3 (4): a014977. doi:10.1101/cshperspect.a014977. PMC 3684003. PMID 23545575.
- ↑ 2.0 2.1 2.2 2.3 2.4 Villa NY, Rahman MM, McFadden G, Cogle CR (2016). "Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies". Viruses. 8 (3): 85. doi:10.3390/v8030085. PMC 4810275. PMID 27011200.
- ↑ 3.0 3.1 3.2 Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N; et al. (1990). "Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome". Blood. 75 (4): 1024–30. PMID 2302454.